F S&P 500
5,058.50 -8.50 (-0.17%) F Dow Jones
37,983.00 -10.00 (-0.03%) F Nasdaq
17,505.25 -66.00 (-0.38%) E-mini Russell 2000 Index Futur
1,982.30 -3.30 (-0.17%) Petróleo
81.08 -0.85 (-1.04%) Oro
2,298.20 -4.70 (-0.20%)
Atara Biotherapeutics, Inc. (ATRA)
Fuera de horario:
Atara Biotherapeutics, Inc.
2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
United States
805 623 4211
https://www.atarabio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 225
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Pascal Touchon D.V.M. | President, CEO & Director | 1.04M | N/D | 1963 |
| Alex Chapman | Vice President of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Ms. Jill Henrich | Executive VP and Global Head of Regulatory Affairs & Quality | N/D | N/D | 1963 |
| Mr. Dan Maziasz | Executive VP & Chief Business Officer | N/D | N/D | N/D |
| Ms. Rajani Dinavahi M.D. | Senior VP & Chief Medical Officer | N/D | N/D | N/D |
Descripción
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Atara Biotherapeutics, Inc. a partir del 29 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 5; Junta: 5; Derechos del accionista: 8; Compensación: 7.
